Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Conference News TCT 2017

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

Todd Neale

November 09, 2017

News Conference News PCR London Valves 2017

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

Shelley Wood

September 27, 2017

News Conference News PCR London Valves 2017

Valve Deterioration and Durability Definitions Now Standardized in New Guide

Shelley Wood

September 25, 2017

News Conference News PCR London Valves 2017

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

Shelley Wood

September 24, 2017

News Conference News ESC 2017

Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days

Michael O'Riordan

August 31, 2017

News Daily News

Permanent Pacemakers Post-TAVR Don’t Increase Adverse Event Risk: Meta-analysis

Ashley Lyles

August 08, 2017

News Industry News

Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing

August 01, 2017

News Daily News

Delirium’s Dangers Following TAVR: More Evidence

Shelley Wood

July 19, 2017

News Daily News

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Michael O'Riordan

June 26, 2017

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Shelley Wood

June 19, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

Michael O'Riordan

June 15, 2017

News Conference News EuroPCR 2017

More Early Stroke With SAVR Than TAVR in SURTAVI

Shelley Wood

May 18, 2017

News Conference News EuroPCR 2017

The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone

Yael L. Maxwell

May 17, 2017

REPRISE III: Lotus Valve Matches CoreValve in First Head-to-Head TAVR Trial

News Conference News EuroPCR 2017

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

Shelley Wood

May 16, 2017

News Industry News

Boston Scientific Closes Symetis Acquisition

May 16, 2017

News Industry News

The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year

May 15, 2017

News Daily News

Balloon Predilation Not Mandatory Before TAVR, Meta-analysis Suggests

Caitlin E. Cox

April 21, 2017

News Conference News ACC 2017

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Shelley Wood

March 24, 2017

News Conference News ISET 2017

Forging Into the Future: Debating the Merits of TAVR in Younger, Futile, and Lower-Risk Patients

Caitlin E. Cox

February 06, 2017

Advertisement

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

Valve Deterioration and Durability Definitions Now Standardized in New Guide

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days

Permanent Pacemakers Post-TAVR Don’t Increase Adverse Event Risk: Meta-analysis

Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing

Delirium’s Dangers Following TAVR: More Evidence

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

More Early Stroke With SAVR Than TAVR in SURTAVI

The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

Boston Scientific Closes Symetis Acquisition

The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year

Balloon Predilation Not Mandatory Before TAVR, Meta-analysis Suggests

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Forging Into the Future: Debating the Merits of TAVR in Younger, Futile, and Lower-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content